Sitaxentan ( DrugBank: Sitaxentan )

1 disease

告示番号	疾患名（ページ内リンク）	臨床試験数
86	肺動脈性肺高血圧症	9

86. 肺動脈性肺高血圧症

臨床試験数 : 1,205 / 薬物数 : 684 - (DrugBank : 124) / 標的遺伝子数 : 100 - 標的パスウェイ数 : 193

diseases per page:

Showing 1 to 9 of 9 diseases

Filter by

No.	TrialID	Date_ enrollment	Date_ registration	Public_title	Scientific_title	Condition	Intervention	Primary_ sponsor	Secondary_ sponsor	Recruitment_ Status	Inclusion_ agemin	Inclusion_ agemax	Inclusion_ gender	Target_ size	Phase	Countries
1	NCT01251848 (ClinicalTrials.gov)	January 2011	1/12/2010	Drug Interaction Between Ritonavir And Sitaxsentan	A Phase 1, Open Label, Randomized, Multiple Dose Study To Assess The Two-Way Drug Interaction Betwee ...	Pulmonary Arterial Hypertension	Drug: Sitaxentan;Drug: Ritonavir;Drug: Sitaxsentan	Pfizer	NULL	Withdrawn	21 Years	55 Years	Both	0	Phase 1	NULL
2	JPRN-JapicCTI-101370	10/12/2010	09/12/2010	Long-Term Open-Label, Safety Study Of SitaxentanSodium In Japanese Pulmonary Arterial Hypertension P ...	A Phase 3, Multi-Center, Open Label Study To Evaluate The Long-Term Safety Of SitaxentanSodium In Ja ...	Pulmonary Arterial Hypertension	Intervention name : Sitaxentansodium INN of the intervention : Sitaxentan Dosage And administration of ...	Pfizer Japan Inc.	NULL		16	80	BOTH	35	Phase 3	NULL
3	NCT01210443 (ClinicalTrials.gov)	November 2010	11/8/2010	Long-Term Open-Label, Safety Study Of SitaxentanSodium In Japanese Pulmonary Arterial Hypertension P ...	A Phase 3, Multi-Center, Open Label Study To Evaluate The Long-Term Safety Of SitaxentanSodium In Ja ...	Hypertension, Pulmonary	Drug: Sitaxentan	Pfizer	NULL	Terminated	16 Years	80 Years	All	2	Phase 3	Japan
4	NCT01244620 (ClinicalTrials.gov)	November 2010	15/11/2010	A Pharmacokinetic Drug-Drug Interaction (DDI) Study Between Sitaxsentan And Sildenafil, And Between ...	A Phase 1, Open Label, Randomized, Four Period, Crossover, Multiple Dose Study To Assess The Pharmac ...	Pulmonary Arterial Hypertension	Drug: sitaxentan;Drug: tadalafil;Drug: sitaxsentan;Drug: sildenafil	Pfizer	NULL	Terminated	21 Years	55 Years	All	16	Phase 1	Singapore
5	JPRN-JapicCTI-101369	20/8/2010	09/12/2010	A 12 Week Safety And Efficacy Study Of SitaxentanSodium In Japanese Pulmonary Arterial Hypertension ...	A Phase 3, Multi-Center, Open Label Study to Investigate Safety and efficacy of SitaxentanTHERAPY in ...	Pulmonary Arterial Hypertension	Intervention name : Sitaxentansodium INN of the intervention : Sitaxentan Dosage And administration of ...	Pfizer Japan Inc.	NULL		16	80	BOTH	35	Phase 3	NULL
6	NCT01204853 (ClinicalTrials.gov)	August 2010	6/8/2010	A 12 Week Safety And Efficacy Study Of SitaxentanSodium In Japanese Pulmonary Arterial Hypertension ...	A Phase 3, Multi-Center, Open Label Study To Evaluate The Safety And Efficacy Of SitaxentanSodium In ...	Hypertension, Pulmonary	Drug: Sitaxentan	Pfizer	NULL	Terminated	16 Years	80 Years	All	2	Phase 3	Japan
7	NCT00995566 (ClinicalTrials.gov)	April 2010	17/9/2009	A Non-Interventional, Patient Registry For The Collection Of Pre-Defined Safety Data In Patients Pre ...	Thelin (SitaxentanSodium) Patient Safety Registry A Non-Interventional, Patient Registry For The Col ...	Pulmonary Arterial Hypertension	Drug: Sitaxentan sodium	Pfizer	NULL	Terminated	18 Years	N/A	All	54	N/A	Belgium;France;Germany;Sweden
8	NCT01445873 (ClinicalTrials.gov)	December 1, 2009	30/9/2011	Pilot Chart Review Study Of SitaxentanSodium (Thelin) In Patients With Pulmonary Arterial Hypertensi ...	NON-INTERVENTIONAL (NI) DRUG STUDY PROTOCOL: THREE-COUNTRY PILOT STUDY FOR RETROSPECTIVE CHART REVIE ...	Pulmonary Arterial Hypertension	Drug: Sitaxentan sodium	Pfizer	NULL	Completed	18 Years	N/A	All	36		NULL
9	NCT00080457 (ClinicalTrials.gov)	May 2003	1/4/2004	Safety and Efficacy Study of SitaxentanSodium (Thelin™) in Patients With Pulmonary Arterial Hyperten ...	A Phase 3, Randomized, Double-Blind, Placebo-Controlled Safety and Efficacy Study of Sitaxsentan Sod ...	Pulmonary Hypertension	Drug: sitaxsentan sodium	Encysive Pharmaceuticals	NULL	Completed	12 Years	75 Years	Both	240	Phase 3	United States

First Previous1Next Last